Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2004-4-20
pubmed:abstractText
Tissue factor pathway inhibitor (TFPI) is the major physiologic inhibitor of the extrinsic coagulation pathway. We have previously shown that TFPI is also a potent inhibitor of endothelial proliferation in vitro and of primary and metastatic tumor growth in vivo. Surprisingly, the antitumor activity of TFPI was demonstrated to be independent of its anticoagulant activity, suggesting a possible nonhemostatic mechanism of action for TFPI in these models. This antitumor mechanism may involve the very low density lipoprotein (VLDL) receptor because the in vitro antiproliferative activity of TFPI is mediated through interaction with the VLDL receptor. In the current study, we identify a 23-amino acid fragment of TFPI (TFPIc23) localized to the C-terminus, which mediates binding to the VLDL receptor. The TFPIc23 peptide inhibits endothelial cell proliferation through an apoptotic mechanism and blocks vessel outgrowth in the in vitro assays, and this activity is mediated through interaction with the VLDL receptor. In vivo, this peptide potently inhibits angiogenesis in Matrigel and chick chorioallantoic membrane models and also inhibits metastatic tumor growth. Our data demonstrate that this VLDL receptor-binding fragment of the TFPI molecule has apoptotic, antiangiogenic, and antitumor activity and suggests a possible mechanism whereby TFPI can regulate angiogenesis and tumor growth independently of its anticoagulant activity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0006-4971
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
103
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3374-80
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed-meshheading:14739228-Angiogenesis Inhibitors, pubmed-meshheading:14739228-Animals, pubmed-meshheading:14739228-Antineoplastic Agents, pubmed-meshheading:14739228-Apoptosis, pubmed-meshheading:14739228-Binding Sites, pubmed-meshheading:14739228-Carcinoma, Lewis Lung, pubmed-meshheading:14739228-Cell Division, pubmed-meshheading:14739228-Chick Embryo, pubmed-meshheading:14739228-Endothelium, Vascular, pubmed-meshheading:14739228-Humans, pubmed-meshheading:14739228-Lipoproteins, pubmed-meshheading:14739228-Mice, pubmed-meshheading:14739228-Mice, Inbred C57BL, pubmed-meshheading:14739228-Neoplasm Metastasis, pubmed-meshheading:14739228-Neovascularization, Physiologic, pubmed-meshheading:14739228-Peptide Fragments, pubmed-meshheading:14739228-Receptors, LDL, pubmed-meshheading:14739228-Umbilical Veins
pubmed:year
2004
pubmed:articleTitle
Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity.
pubmed:affiliation
EntreMed, Inc, 9640 Medical Center Dr, Rockville, MD 20850,USA. toddh@entremed.com
pubmed:publicationType
Journal Article